What's in Myovant Sciences GmbH's pipeline?

Myovant Sciences GmbH has 2 drugs in our index: 1 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Myovant Sciences GmbH's portfolio?

Top competitors by shared drug class: Anna Posadzy-Małaczyńska, Beni-Suef University, Brigham and Women's Hospital, El Shatby University Hospital for Obstetrics and Gynecology, Erasmus Medical Center.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/myovant-sciences-gmbh.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Myovant Sciences GmbH — Portfolio Competitive Intelligence Brief

Myovant Sciences GmbH pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Estradiol/norethindrone acetate	Estradiol/norethindrone acetate	marketed	Hormone replacement therapy (HRT)	Estrogen receptor alpha and beta; progesterone receptor	Women's Health / Endocrinology
Placebo for relugolix	Placebo for relugolix	phase 3

Therapeutic area mix

Women's Health / Endocrinology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Anna Posadzy-Małaczyńska · 1 shared drug class
Beni-Suef University · 1 shared drug class
Brigham and Women's Hospital · 1 shared drug class
El Shatby University Hospital for Obstetrics and Gynecology · 1 shared drug class
Erasmus Medical Center · 1 shared drug class
Massachusetts General Hospital · 1 shared drug class
Peking Union Medical College Hospital · 1 shared drug class
Scientific Research Institute of Public Health, Russian Federation · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Myovant Sciences GmbH:

Cite this brief

Drug Landscape (2026). Myovant Sciences GmbH — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/myovant-sciences-gmbh. Accessed 2026-05-16.